2022 Q4 Form 10-K Financial Statement

#000106299322021269 Filed on October 31, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $410.8K $523.6K $2.389M
YoY Change -3.92% -2.97% 0.0%
% of Gross Profit
Research & Development $124.0K $451.0K $788.7K
YoY Change 127.42% 142.29% 0.82%
% of Gross Profit
Depreciation & Amortization $5.650K $6.020K $24.35K
YoY Change -9.31% -8.37% -4.81%
% of Gross Profit
Operating Expenses $563.8K $1.004M $3.292M
YoY Change 10.31% 32.98% 0.2%
Operating Profit
YoY Change
Interest Expense $97.82K -$268.6K $273.0K
YoY Change -67.18% -250.4% 128.44%
% of Operating Profit
Other Income/Expense, Net $0.00 $64.25K $79.14K
YoY Change -100.0% 10432.79% 1518.4%
Pretax Income -$684.5K -$1.208M -$3.464M
YoY Change 222.44% 109.9% 115.98%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$684.5K -$1.208M -$3.464M
YoY Change 222.44% 109.9% 115.98%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$0.12
Diluted Earnings Per Share -$0.02 -$36.80K -$0.12
COMMON SHARES
Basic Shares Outstanding 32.79M shares 29.80M shares
Diluted Shares Outstanding 32.79M shares 29.80M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.8K $471.9K $471.9K
YoY Change -57.99% -38.97% -38.97%
Cash & Equivalents $166.8K $471.9K
Short-Term Investments
Other Short-Term Assets $366.6K $429.3K $429.3K
YoY Change 14.9% 26.63% 26.63%
Inventory
Prepaid Expenses $366.6K $429.3K
Receivables $72.93K $85.36K $85.36K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $606.3K $986.6K $986.6K
YoY Change -20.58% -14.69% -14.69%
LONG-TERM ASSETS
Property, Plant & Equipment $545.8K $551.4K $4.700M
YoY Change -4.17% -4.23% -0.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.695M $4.700M $4.700M
YoY Change -0.5% -0.52% -0.52%
TOTAL ASSETS
Total Short-Term Assets $606.3K $986.6K $986.6K
Total Long-Term Assets $4.695M $4.700M $4.700M
Total Assets $5.301M $5.687M $5.687M
YoY Change -3.3% -3.3% -3.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $488.1K $321.9K $321.9K
YoY Change 81.48% 94.07% 94.07%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $539.8K $350.0K $350.0K
YoY Change 86.81% 75.07% 75.07%
LONG-TERM LIABILITIES
Long-Term Debt $1.491M $1.365M $1.365M
YoY Change 43.72% 39.72% 39.72%
Other Long-Term Liabilities $355.9K $373.9K $373.9K
YoY Change 240.05% -15.36% -15.36%
Total Long-Term Liabilities $1.847M $1.738M $1.738M
YoY Change 61.71% 22.57% 22.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $539.8K $350.0K $350.0K
Total Long-Term Liabilities $1.847M $1.738M $1.738M
Total Liabilities $2.387M $2.088M $2.088M
YoY Change 66.77% 29.05% 29.05%
SHAREHOLDERS EQUITY
Retained Earnings -$23.69M -$23.01M
YoY Change 17.72%
Common Stock $32.79K $32.79K
YoY Change 22.48% 22.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.914M $3.599M $3.599M
YoY Change
Total Liabilities & Shareholders Equity $5.301M $5.687M $5.687M
YoY Change -3.3% -3.3% -3.3%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022
OPERATING ACTIVITIES
Net Income -$684.5K -$1.208M -$3.464M
YoY Change 222.44% 109.9% 115.98%
Depreciation, Depletion And Amortization $5.650K $6.020K $24.35K
YoY Change -9.31% -8.37% -4.81%
Cash From Operating Activities -$305.1K -$910.5K -$2.694M
YoY Change -18.89% 19.54% -5.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities $0.00 0.000 $2.393M
YoY Change 864.15%
NET CHANGE
Cash From Operating Activities -$305.1K -910.5K -$2.694M
Cash From Investing Activities
Cash From Financing Activities $0.00 0.000 $2.393M
Net Change In Cash -$305.1K -910.5K -$301.4K
YoY Change -18.89% 19.54% -88.43%
FREE CASH FLOW
Cash From Operating Activities -$305.1K -$910.5K -$2.694M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
773279 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
usd
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-07-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Public Float
EntityPublicFloat
15297475 usd
CY2022 dei Auditor Firm
AuditorFirmId
731
CY2022 dei Auditor Name
AuditorName
DAVIDSON & COMPANY LLP
CY2022 dei Auditor Location
AuditorLocation
Vancouver, Canada
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
471918 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
90268 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
773279 usd
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3378826 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
471918 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
773279 usd
CY2022 us-gaap Other Operating Income
OtherOperatingIncome
79137 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-left: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of Estimates</b></span></span></p> <p style="margin-left: 35.45pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant areas requiring the use of estimates include the carrying value and recoverability of mineral properties and the recognition of deferred tax assets based on the change in unrecognized deductible temporary tax differences. Actual results could differ from those estimates and would impact future results of operations and cash flows.</span></span></p> </div>
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.09
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
805000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.82
CY2022 us-gaap Property Plant And Equipment Depreciation Methods
PropertyPlantAndEquipmentDepreciationMethods
straight-line basis
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-left: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Concentration of credit risk</b></span></span></p> <p style="margin-left: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial instrument which potentially subjects the Company to concentration of credit risk is cash. The Company maintains cash in bank accounts that, at times, may exceed federally insured limits. As of July 31, 2022, and 2021, the Company has not exceeded the federally insured limit. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts.</span></span></p> </div>
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3038500 shares
ryes Number Of Common Share Purchase Warrants Issued
NumberOfCommonSharePurchaseWarrantsIssued
6308310 shares
ryes Number Of Common Share Purchase Warrants Issued
NumberOfCommonSharePurchaseWarrantsIssued
6308310 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3038500 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.02
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1005000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1338500 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.2
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
110000 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.5
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2233500 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.02
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1313 usd
CY2022 us-gaap Income Tax Reconciliation Deductions Other
IncomeTaxReconciliationDeductionsOther
282000 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12337006 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.95
CY2022 ryes Class Of Warrant Or Right Expired Unexercised
ClassOfWarrantOrRightExpiredUnexercised
11196 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12471999 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.27
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
166666 shares
CY2021 ryes Warrants Issued Weighted Average Exercise Price
WarrantsIssuedWeightedAverageExercisePrice
1.36
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
5787286 shares
CY2021 ryes Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
1.3
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6851379 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.14
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
6017500 shares
CY2022 ryes Warrants Issued Weighted Average Exercise Price
WarrantsIssuedWeightedAverageExercisePrice
0.76
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
531873 shares
CY2022 ryes Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
1.21
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12337006 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.95
CY2021 us-gaap Income Tax Reconciliation Deductions Other
IncomeTaxReconciliationDeductionsOther
815000 usd

Files In Submission

Name View Source Status
0001062993-22-021269-index-headers.html Edgar Link pending
0001062993-22-021269-index.html Edgar Link pending
0001062993-22-021269.txt Edgar Link pending
0001062993-22-021269-xbrl.zip Edgar Link pending
exhibit23-1.htm Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
form10kxz001.jpg Edgar Link pending
form10kxz002.jpg Edgar Link pending
form10kxz003.jpg Edgar Link pending
form10kxz004.jpg Edgar Link pending
form10kxz005.jpg Edgar Link pending
form10kxz006.jpg Edgar Link pending
form10kxz007.jpg Edgar Link pending
form10kxz008.jpg Edgar Link pending
form10kxz009.jpg Edgar Link pending
form10kxz012.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
ryes-20220731.xsd Edgar Link pending
Show.js Edgar Link pending
ryes-20220731_cal.xml Edgar Link unprocessable
ryes-20220731_pre.xml Edgar Link unprocessable
ryes-20220731_lab.xml Edgar Link unprocessable
ryes-20220731_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10k_htm.xml Edgar Link completed